GRAIL’s mission is to detect cancer early, when it can be cured
Why early matters
Survival rates are higher when cancer is diagnosed at earlier stages.
However, effective screening only exists for a few cancer types, and most cancer is detected at later stages, when survival rates are much lower.
Late-Stage
Survival Rate
1X
Early-Stage
Survival Rate
5 - 10X higher
Aravanis AM, Lee M, Klausner RD. Cell. 2017; 168(4):571–574, 9.
Working to transform cancer care through early detection
At GRAIL, our mission is to improve and save lives through early cancer detection, and we are developing our test in a rigorous way to deliver our test to patients safely and effectively.
We need to change the trajectory of cancer mortality and bring stakeholders together to enable broad adoption of innovative, safe, and effective technology that can transform cancer control and cancer care.
There may be no greater opportunity in healthcare to make a significant impact to public health. We are navigating uncharted territory because no tool like this exists today. The path isn’t easy, but we believe it is the right one — for patients, for providers, and for communities and healthcare systems around the world.
Learn more from Josh Ofman, MD, MSHS, Chief of Corporate Strategy and External Affairs on how GRAIL is working to transform cancer care through early detection.
GRAIL’s approach
GRAIL aims to develop blood tests to detect cancer early, when treatment may be more successful.
To achieve this, we are building intelligent models to identify clinically actionable information from vast amounts of tumor genome data obtained through high-intensity sequencing.
Where hope meets rigor
At GRAIL, we’re unrelenting in the pursuit of our mission and will not stop until we find a better way. With the best talent in biology, clinical science, bioinformatics, deep learning, and engineering along with the passion of our leadership, our goal is to greatly decrease global cancer mortality.